Skip to main content
Premium Trial:

Request an Annual Quote

Geneka, Genomatix Enter Functional Genomics, Tech Development Alliance

NEW YORK, Oct. 23 – Canadian proteomic firm Geneka Biotechnology and Genomatix Software, a bioinformatics company based in Munich, Germany, have inked a researcher alliance that focuses on functional genomics and technology development, Geneka said on Tuesday.

The partnership, which will span eight to 10 years, initially will be a drug-discovery alliance that will center on human proteomic regulators, according to Geneka. Other parts of the deal, which were not specified, have to do with technology development, said Denis Goyette, Geneka’s director of finance.

Goyette said that an undisclosed product based on technology already developed by the alliance is expected to reach the market in the current quarter. That product, he said, will be marketed in the United States, Europe, and Japan.

Financial terms of the agreement were disclosed.

Geneka currently markets the P.R.O.M. DNA microarray chip, which carries probes for all known or suspected human transcription regulators available from public genome sequences. Genomatix Software will provide proprietary bioinformatics services to analyze the data generated by P.R.O.M.